NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.

Abstract

The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary carcinoma of the urethra). These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non-muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non-muscle invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody-drug conjugates for metastatic bladder cancer.

• Authors: Thomas W Flaig, Philippe E Spiess, Michael Abern, Neeraj Agarwal, Rick Bangs, Stephen A Boorjian, Mark K Buyyounouski, Kevin Chan, Sam Chang, Terence Friedlander, Richard E Greenberg, Khurshid A Guru, Harry W Herr, Jean Hoffman-Censits, Amar Kishan, Shilajit Kundu, Subodh M Lele, Ronac Mamtani, Vitaly Margulis, Omar Y Mian, Jeff Michalski, Jeffrey S Montgomery, Lakshminarayanan Nandagopal, Lance C Pagliaro, Mamta Parikh, Anthony Patterson, Elizabeth R Plimack, Kamal S Pohar, Mark A Preston, Kyle Richards, Wade J Sexton, Arlene O Siefker-Radtke, Matthew Tollefson, Jonathan Tward, Jonathan L Wright, Mary A Dwyer, Carly J Cassara, Lisa A Gurski
• Journal: Journal of the National Comprehensive Cancer Network : JNCCN (J Natl Compr Canc Netw) Vol. 20 Issue 8 Pg. 866-878 (08 2022) ISSN: 1540-1413 [Electronic] United States
• PMID: 35948037 (Publication Type: Journal Article)

Topics

• Administration, Intravesical
• Carcinoma, Transitional Cell (pathology)
• Humans
• Male
• Neoplasm Invasiveness (pathology)
• Neoplasm Recurrence, Local (pathology)
• Neoplasm Staging
• Urinary Bladder Neoplasms (drug therapy, therapy)